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Abstract
Transplanted neural stem and progenitor cells (NSCs) produce mostly astrocytes in injured spinal cords. Lithium stimulates
neurogenesis by inhibiting GSK3b (glycogen synthetase kinase 3-beta) and increasing WNT/beta catenin. Lithium
suppresses astrogliogenesis but the mechanisms were unclear. We cultured NSCs from subventricular zone of neonatal rats
and showed that lithium reduced NSC production of astrocytes as well as proliferation of glia restricted progenitor (GRP)
cells. Lithium strongly inhibited STAT3 (signal transducer and activator of transcription 3) activation, a messenger system
known to promote astrogliogenesis and cancer. Lithium abolished STAT3 activation and astrogliogenesis induced by a
STAT3 agonist AICAR (5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside), suggesting that lithium suppresses
astrogliogenesis by inhibiting STAT3. GSK3b inhibition either by a specific GSK3b inhibitor SB216763 or overexpression of
GID5-6 (GSK3b Interaction Domain aa380 to 404) did not suppress astrogliogenesis and GRP proliferation. GSK3b inhibition
also did not suppress STAT3 activation. Together, these results indicate that lithium inhibits astrogliogenesis through non-
GSK3b-mediated inhibition of STAT. Lithium may increase efficacy of NSC transplants by increasing neurogenesis and
reducing astrogliogenesis. Our results also may explain the strong safety record of lithium treatment of manic depression.
Millions of people take high-dose (.1 gram/day) lithium carbonate for a lifetime. GSK3b inhibition increases WNT/beta
catenin, associated with colon and other cancers. STAT3 inhibition may reduce risk for cancer.
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Introduction
Transplanted neural stem cells (NSCs) produce mostly astro-
cytes in injured spinal cords, due in part to cytokines released by
activated microglia or macrophages [1] e.g. IL-6 [2,3], ciliary
neurotrophic factor [4,5], or leukemia inhibiting factor [6,7],
NSCs produce relatively few neurons (,20%) that integrate into
host spinal cord [8,9,10,11,12]. When NSC are transplanted as a
therapy to replace neurons in injured brain and spinal cord [13],
excess astrogliosis may reduce efficacy of the therapies. Astro-
gliogenesis may also hamper axon outgrowth.
Long used to treat bipolar depression and hematopoietic
disorders [14], lithium stimulates NSCs neurogenesis in the
hippocampus [15] and subventricular zone [16], causing sustained
increases of gray matter volume in patients [17,18,19,20]. Lithium
also stimulates transplanted NSCs to produce more neurons [21]
as well as axonal growth in injured spinal cord [22,23]. Other
glycogen synthetase kinase (GSK) blockers mimic these lithium
effects on neurogenesis and regeneration.
Recent study shows lithium inhibits GSK3b and invokes
downstream effects on NSCs development. It increases beta-
catenin accumulation [24], which combines with WNT to
stimulate NSC proliferation and neurogenesis. RNAi inhibition
of beta-catenin abolishes these lithium-induced effects [25]. Beside
the effect on stimulating NSCs proliferation and neurogenesis,
lithium is also found reducing astrogliogenesis by NSCs [26], but
the mechanisms underlay remains an enigma.
Lithium inhibits multiple messenger systems [27,28], including the
JAK/STAT3 pathway [29] known to stimulate astrocytosis [30]. We
therefore studied the effects of lithium and other GSK3b blockers on
astrogliogenesis by NSCs isolated from neonatal rat brains. Both
lithium and another GSK3b inhibitor SB216763 stimulated
neurogenesis but only lithium suppressed astrogliogenesis by NSCs.
In addition, analysis of restricted progenitor cell proliferation revealed
that both lithium and SB216763 promotes neuronal restricted
progenitor (NRP) cell proliferation, but only lithium inhibited the
proliferation of GRPs. Further investigation showed that lithium not
only strongly inhibited STAT3 activation, but also abolished the
effect of a STAT3 agonist AICAR on inducing STAT3 activation
and astrogliogenesis, indicating that lithium suppresses astrogliogen-
esis through inhibiting STAT3. Nevertheless, neither specific GSK3b
inhibitor SB216763 nor molecular blockade of GSK3b with GID5-6
overexpression inhibited astrogliogenesis or STAT3 activation
induced by serum or AICAR, These results together indicate that
lithium inhibits astrogliogenesis through a non-GSK3b-mediated
inhibition of STAT3.
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Neural Stem Cells and Progenitor Cells
Growing NSC in growth media expectedly produced heteroge-
neous cultures of cells that expressed neuronal, astrocytic, and
oligodendroglial markers. After 7 days in growth in serum-free
media (DMEM with bFGF and EGF), NSCs proliferated and
congregated in loose colonies that expressed nestin (Figure 1A), an
intermediate filament protein present in NSC and progenitor cells
[37]. The cells often formed neurospheres. After dissociation,
replating, and growth in 10 ng/ml bFGF and EGF for 24 hours,
the cells were unipolar or bipolar with short processes (Figure 1B)
and almost all (9760.85%) expressed nestin (Figure 1C). Very few
cells (1.0060.43%) expressed GFAP, characteristic of mature
astrocytes (Figure. 1D). Likewise, only 1.0060.81% expressed
Tuj1 (Figure. 1E), a neuronal marker. Only 0.5060.21%
expressed GalC (Figure 1F), a major myelin galactosphingolipid
and oligodendroglial marker. Many cells expressed A2B5 or PSA-
NCAM, presumptive markers [38,39] for GRPs and neuronal
restricted progenitors (NRPs) respectively comprising 39.063.03%
(Figure 1G) and 16.064.58% (Figure 1H) of the cultures.
When transferred to neurobasal media containing B27 (NB27,
Invitrogen), many of the cells began to show mature neuronal,
astrocytic, and oligodendroglial markers. After 7 days in NB27
media, 32.161.4% of the cells expressed the neuronal marker
Tuj1 and 42.861.9% expressed the astrocytic marker GFAP
(Figure 2C1). The cells expressing Tuj1 or GFAP also had
respectively the morphology of neurons and astrocytes. In general,
astrocytes outnumbered neurons.
In summary, NSC cultures produced progenitor and differen-
tiated cells. In serum-free growth media, the cells proliferated and
formed loose colonies of nestin-expressing cells and neurospheres.
Many cells expressed A2B5 or PSA-NCAM, presumptive markers
for glial-restricted and neural-restricted progenitor cells. Relatively
few cells expressed mature neuronal, astrocytic, and oligoden-
droglial markers. However, when grown for 7 days in NB27
medium, NSCs produce mostly GFAP+ astrocytes and Tuj1+
neurons, the former more than the latter.
GSK3b Inhibition Promotes NSCs Proliferation in NB27
Medium
Lithium and other GSK3b inhibitors stimulate growth of NSC
and progenitor cells [21,25,40]. We therefore examined the effects
of lithium and the GSK3b inhibitor SB216763 on NPC’s grown in
NB27 medium. Even in the absence of added growth factors,
NSCs and NPC’s continued to proliferate in NB27 (Figure 2A)
and SB216763 was more potent than lithium in stimulating
proliferation in NB27 without growth factors. Lithium (1 mM)
increased total cell number by 1.1 fold after 7 days. In contrast,
SB216763 (10 mM) markedly stimulated NSC proliferation,
increasing total cell number by 1.4 fold (p,0.05 compared to
lithium-treated cultures) after 7 days (Figure 2B).
Lithium but not SB216763 Suppresses Astrogliogenesis
After 7 days in NB27, many cells began showing mature astrocytic
marker GFAP and neuronal marker Tuj1. We stained and counted
the cells, estimating the total numbers and percentage of cells of each
lineage. While both lithium and SB216763 enhanced neurogenesis,
only lithium suppressed astrogliogenesis. Lithium significantly
increased the number of Tuj1 positive cells by 1.2860.03 fold in
0.5 mM LiCl (P,0.05), 1.4760.06 fold in 1.0 mM LiCl (P,0.05),
1.3360.03 fold in 3.0 mMLiCl (P,0.05), 0.6660.02foldin5.0 mM
LiCl (P,0.05), 2.2560.07 fold in 10 mM SB216763 (P,0.05) from
control level (Figure 2C3). Conversely, lithium reduced the GFAP-
positive cellsnumber from control level to 0.7560.05 fold in 0.5 mM
LiCl (P,0.05), 0.6460.02 in 1.0 mM LiCl (P,0.05), 0.5560.02 in
3.0 mM LiCl (P,0.05), 0.5460.03 in 5.0 mM LiCl (P,0.05).
Conversely, SB216763 treatment did not reduced astrocytes number
(0.9060.06 fold versus Control, P.0.05, Figure 2C2). We also found
the similar tendency with S100beta immunostaining (Figure S1),
whichisanotherastrocytesmarker.Theseresultsindicatethatlithium
and SB216763 exert different effects on astrogliogenesis.
Western blots confirmed the decrease of GFAP and increase of
Tuj1 protein in the lithium-treated cultures (Figure 2D). Com-
pared to control untreated cultures, 5 mM LiCl treatment reduced
GFAP expression by 50% (p,0.01) and LiCl treatment increased
Tuj1 expression, particularly at 1 mM. Lithium had a higher dose-
response curve for suppressing astrogliogenesis than neurogenesis.
The inhibitory effects of lithium on astrocytic production
continued to increase up to 5 mM while the stimulatory effects
of lithium on neurons peaked at 1 mM.
Lithium suppression of astrogliogenesis was most prominent at
lithium concentrations $3 mM. At these doses, lithium may be toxic
to cells, hence reducing the number of astrocytes by causing apoptosis
[41] rather than by inhibiting astrogliogenesis. We therefore studied
theeffectsof lithiumandSB216763on apoptosisin the cultures, using
the TUNEL assay [42,43]. Neither 10 mM SB216763 nor 1–3 mM
LiClincreased apoptosisofcellsculturedinNB27mediumfor7days.
However, higher (5 mM) concentrations of LiCl nearly doubled the
number of TUNEL-positive cells (Figure 2E). While lithium toxicity
may partly explain the decline in astrocytes at 5 mM, it cannot
account for the reduction of astrocyte count at 3 mM. we observed
that lithium and SB2 induced neurite spreading and branching,
w h i c hm a yd u ot ot h e i ri n h i b i t i o no nG S K 3 b [44].
In summary, analysis of cell counts of Tuj1- and GFAP-
expressing cells revealed that, while both lithium and SB216763
stimulated neurogenesis, only lithium suppressed astrogliogenesis.
SB216763 increased the number of neurons but did not reduce the
number of astrocytes. Lithium increased the number of neurons
and reduced the number of astrocytes. Higher concentrations of
lithium (3 mM) were required to suppress astrogliogenesis than to
stimulate neurogenesis (1 mM). Although lithium increased
apoptosis of astrocytes at 5 mM, it did not do so at 3 mM,
suggesting that the reduction of astrocytes at 3 mM was not due to
lithium-induced apoptosis.
Lithium and SB216763 Effects on GRP Proliferation
Both lithium and SB216763 reduced the percentage of GRPs,
as measured by A2B5 immunostaining. The percentage of A2B5+
cells fell from 3961.6% in control cultures to 2561.7% after 2 day
in 3 mM LiCl culture. SB216763 also reduced the percent of
A2B5+ cells but not as much as lithium (Figure 3A). Combining
the percentage and cell count data (Figure 2A) indicated that the
actual number of GRPs increased with time in untreated and
SB216763-treated cultures. Lithium-treated cultures however,
showed little or no increase in A2B5+ cell counts, suggesting that
lithium inhibits proliferation or production of A2B5+ cells.
To confirm this hypothesis, we stained the cells for Ki-67, a
nuclear and nucleolar protein that increases with somatic cell
proliferation [45,46]. Lithium dramatically reduced the Ki-67
positive fraction of A2B5+ cells to 38%, compared to 68% in
control untreated cultures. In SB216763-treated cultures, Ki-67
positive fraction was 64%, not significantly different (p.0.05) from
control untreated cultures (Figure 3B).
In summary, lithium (3 mM) reduced both the percentage and
the number of GRPs but GSK3b blocker SB216763 did not.
Lithium markedly reduced the fraction of A2B5+ cells that stained
for Ki-67, a nuclear marker that reflects cell division, from 68% in
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significantly alter the fraction of Ki-67 labeled A2B5+ cells,
confirming that lithium but not SB216763 suppressed proliferation
of GRPs.
Lithium and SB216763 Effects on NRP Proliferation
To assess whether lithium and SB216763 stimulated prolifer-
ation of NRP cells, we assessed the effects of these drugs on PSA-
NCAM expressing cells. Most Tuj1+ cells co-localized with PSA/
Figure 1. Heterogeneity of primary NSCs. Primary rat NSCs were cultured in growth medium containing 10 ng/ml bFGF and 10 ng/ml EGF for 7
days. A. Neurospheres formed and expressed nestin (A1, green). B. A phase image of adherent NSCs. C–H. Immunostaining of nestin (C, red), GFAP
(D, green), Tuj1 (E, red), and GalC (F, red), A2B5 (G, red) and PSA-NCAM (H, green). Nuclei were stained with Hoechst 33342 (DAPI, blue). The table lists
percentages of each cell subpopulation relative to total cell count. Data are expressed as mean 6 sem averaged from four independent experiments.
The scale bar indicates 100 mm.
doi:10.1371/journal.pone.0023341.g001
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e23341Figure 2. Inhibition of GSK3b regulates NSC differentiation. A. Rat NSCs were cultured in NB27 medium supplemented with LiCl (1 mM),
SB216763 (10 mM), or no treatment (control). Cell numbers were estimated with the CyQUANT assay. B. The total cell numbers of untreated (0 mM),
LiCl-treated (0.5, 1.0, 3.0, 5.0 mM) and SB216763-treated (10 mM) cultures at 1, 3 and 7 days after passage. C. NSCs were grown for 7 days in NB27
with LiCl (0.5, 1.0, 3.0, 5.0 mM) or SB216763 (10 mM) and then stained for DAPI (blue), Tuj1 (red), and GFAP (green). The photomicrographs (C1) show
representative fields from each treatment group (3 mM Lithium, scale bar=50 mm). The graphs show actual number counts of GFAP+ cells (C2) and
Tuj1+ cells (C3), normalized to untreated control counts. D. The expression of GFAP and Tuj1 on NSCs treated with LiCl (0, 0.5, 1.0, 3.0, 5.0 mM) or
SB216763 (SB2, 10 mM) after growing 7 days. E1. NSCs were treated with LiCl (0, 0.5, 1.0, 3.0, 5.0 mM) or SB216763 (SB2, 10 mM) for 7 days and
apoptotic cells were detected by TUNEL assay (E1, green). Red arrows indicate the typical morphology of apoptotic cells (left two panels, scale
bar=5 mm), the right 6 panels show the staining of TUNEL+ cells in different treatment groups. Nuclei were stained with Hoechst 33342 (blue, scale
bar=25 mm). E2. Percentages of TUNEL+ cells treated with LiCl and SB216763 at indicated time. Data are expressed as mean 6 sem from three
independent experiments (n=3, * denotes P,0.05 vs. control, one way ANOVA with Dunnett’s post-test).
doi:10.1371/journal.pone.0023341.g002
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e23341Figure 3. Inhibition of GSK3b differentially regulates progenitor cell proliferation. A1. Immunostaining for A2B5 (green) and Hoechst
33342 (blue). NSCs were grown for 2 days in NB27 media containing LiCl (0, 0.5, 1.0, 3.0, 5.0 mM), or SB216763 (SB2, 10 mM). A2. Quantification of
A2B5+ cells as a percentage of total cell count for each LiCl dose and SB216763. B1. The proliferating A2B5+ cells identified by immunostaining for Ki-
67 (red) and A2B5 (green). Cells were treated with LiCl or SB216763 for 24 h. B2. Percentages of Ki-67+ cells amongst A2B5+ cells cultured for 24 h in
control, 3 mM LiCl, or SB216763-treated NSCs. C1. PSA-NCAM+ (green) co-localized with Tuj1 (red) at this stage, pictures show the percentage of
PSA-NCAM+ cells in NSCs treated with LiCl (0, 0.5, 1, 3, 5 mM) or SB216763 (10 mM) for 5 days. C2. The percentage of PSA-NCAM+ cells relative to
total cell count. D1. The proliferating PSA-NCAM+ cells identified by immunostaining with Ki-67 (red) and PSA-NCAM (green) after 4 days. D2. The
percentage of double Ki-67+/PSA-NCAM+/cells among total PSA-NCAM+ cells. Data are expressed as mean 6 sem from three independent
experiments, * denotes P,0.05 vs. control (one way ANOVA with Dunnett’s post-test).
doi:10.1371/journal.pone.0023341.g003
Lithium Suppresses Astrogliogenesis via STAT3
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e23341NCAM after 5 days of differentiation (Figure S3). Both lithium and
SB216763 significantly increased percentages of PSA-NCAM+
cells in 5-day NB27 cultures, i.e. 9% in control cultures compared
to 34% in 1 mM LiCl and 41% in 10 mM SB216763-treated
cultures (Figure 3C). Analysis of the cell counts indicates that both
drugs significantly increased the number of NRPs in the culture.
Double staining for Ki-67 and PSA-NCAM revealed that both
lithium and SB216763 robustly increased the Ki-67 fraction of
PSA-NCAM+ cells, i.e. from 14% in control cultures to 51% in
1 mM LiCl and 64% in SB216763-treated cultures (Figure 3D).
This suggests that both lithium and SB216763 enhanced
production or proliferation of NRPs in the cultures.
In summary, GSK3b blockade by lithium or SB216763
stimulated production of more neurons. Double staining for Ki-
67 and PSA-NCAM revealed that both drugs enhanced
production or proliferation of NRPs.
Lithium Effects on JAK/STAT3 Activation and
Astrogliogenesis
JAK/STAT3 regulates astrocytic production by NSCs. Molec-
ular suppression of STAT3 gene expression or pharmacological
inhibition of STAT3 activity markedly reduces astrogliogenesis
[30,47,48]. One recent study [29] reported that very high
concentrations of LiCl (20 mM) blocked STAT3 activation
induced by lipopolysaccharide (LPS) or interferon in astrocytes.
Since our experiments showed that lower LiCl concentrations
(3 mM) suppressed astrocytosis, we were interested to know
whether this concentration of lithium would block STAT3
activation induced by gentler stimuli.
Serum induces astrogliogenesis through STAT3 activation [49].
We grew NSCs in NB27 medium for 7 days with 0.5% serum and
used Western blots to measure phosphorylated Tyr705 STAT3 (P-
Tyr705-STAT3). Phosphorylation at Tyr-705 activates STAT3,
causing dimmer formation, nuclear translocation, and regulation
of gene expression [50]. P-Tyr-705 STAT3 started increasing by
2 hours and reached 176 baseline (time 0) levels at 24 hours.
Application of 3 mM lithium suppressed P-Tyr705-STAT3 to 46
baseline at 24 hours (P,0.01, Figure 4A). Lithium reduced
expression of P-Tyr705-STAT3 in a dose dependent manner
after 24 hour of treatment (Figure 4B). Total STAT3 did not
change at all time points.
The STAT3 agonist AICAR induces astrogliogenesis by
activating STAT3 [51]. Applying 1 mM AICAR markedly
increased cells exhibiting astrocytic morphology (Figure 4C),
stimulated P-Tyr705-STAT3 and GFAP expression (Figure 4D)
after 24 hours. However, treatment of 3 mM LiCl dramatically
reduced the cells of typical glia morphology (Figure 4C) and
suppressed the induced up-regulation of P-Tyr705-STAT3 and
GFAP (Figure 4E) after 24 h. Immunostaining showed that
lithium markedly reduced GFAP expression after 3 days in both
control untreated and AICAR-treated cultures (Figure 4F, 4G).
In summary, both serum and AICAR stimulate astrocytosis by
activating STAT3. We confirmed that adding 0.5% serum
increased P-Tyr705-STAT3 to 176 of baseline (pre-treatment)
levels, associated with increased astrocytosis and GFAP at
24 hours. Adding 3 mM LiCl reduced P-Tyr705-STAT3 to 46
of baseline and prevented the astrocytosis. The STAT3 agonist
AICAR likewise activated STAT3 and increased astrocytes and
expression of P-Tyr705-STAT3. Applying 3 mM LiCl to the
culture dramatically reduced the number of cells expressing
GFAP in control and AICAR-treated cultures. These data
indicate that lithium blocks STAT3 activation and prevents
astrocytosis.
Effect of SB216763 on JAK/STAT3 Activation and
Astrogliogenesis
Before assessing the effects of the GSK3b blocker SB216763 on
STAT3 activation and astrocytosis, we verified that lithium and
SB216763 blocked GSK3b mediated phosphorylation of beta-
catenin, a widely used assay of GSK3b activity [34,36,52]. As
shown in Figure 5A, 30 minutes of treatment with 5–20 mM of
LiCl significantly reduced phosphorylated beta-catenin (p-beta-
catenin). SB216763 likewise inhibited formation of p-beta-catenin.
Exposing NSC cultures to 0.5% serum significantly increased
activated STAT3 (P-Tyr-705-STAT3) by 2 hours and to very high
levels by 24 hours (Figure 5B). Both 3 and 5 mM LiCl reduced P-
Tyr705-STAT3 levels compared to 0 mM LiCl but neither 10 nor
20 mM SB216763 reduced P-Tyr705-STAT3 levels (Figure 5C).
Another GSK3b blocker SB415286 did not reduce P-Tyr705-
STAT3 either. In fact, both drugs increased P-Tyr705-STAT3
levels slightly. The Jak/STAT3 inhibitor Stattic (10 mM) markedly
reduced P-Tyr705-STAT3 levels. Similarly, 3–5 mM lithium
reduced P-Tyr705-STAT3 induced by the STAT3 agonist
AICAR but SB216763 did not (Figure 5D). Lithium reduced
GFAP levels, AICAR increased GFAP, lithium partially blocked
the AICAR induced GFAP rise, but SB216763 did not (Figure 5E).
In summary, pharmacological blockade by SB216763 did not
block STAT3 activation, manifested by no differences of P-
Tyr705-STAT3 levels induced by serum or AICAR. We
confirmed that SB216763 blocked GSK3b mediated phosphory-
lation of beta-catenin and is approximately 1000 times more
potent than lithium. Increasing the dose of SB216763 to 20 mM
did not block STAT3 either. Another GSK3b blocker SB415286
did not prevent the STAT3 activation by serum. SB216763 also
did not block AICAR-induced increase in GFAP. In contrast,
lithium blocked the AICAR-induced rise in P-Tyr705-STAT3 and
reduction of GFAP.
Effect of GID5-6 on STAT3 activation and astrogliogenesis
GID5-6 is a specific molecular blocker of GSK3b, overexpres-
sion of GID5-6 inhibits GSK3b activity in vitro. The GID5-6 and
GID5-6LP were myc-tagged so that we could tell which cells were
transfected. The AmaxaH NucleofectorH Kit yielded 50–60%
transection efficiency (Figure 6A). Transfection with GID5-6
upregulated GSK3b phosphorylation, identified with a Ser-9
GSK3b antibody and indicative of GSK3b inhibition (Figure 6B).
However, neither GID5-6 nor GID5-6LP blocked the increase of
P-Tyr705-STAT3 induced by 0.5% serum while lithium did
(Figure 6C). GID5-6 transfection increased total cell numbers after
seven days (1.26,n = 3 ,p ,0.05) compared to GID5-6LP
transfection (Figure 6D, 6E) but not the number of GFAP-
expressing cells (Figure 6F, 6G).
In summary, transfection and overexpression of GID5-6
effectively inhibited GSK3b activity and stimulated proliferation
of NPC but did not stop inhibition STAT3 phosphorylation or
GFAP production. Thus, lithium inhibits STAT3 activation and
astrogliogenesis through a mechanism not involving GSK3b.
Discussion
Wexler, et al. [25] previously reported that lithium stimulates
hippocampal neurogenesis by inhibiting GSK3b and elevating
beta-catenin. Our experiments confirmed that both lithium and
the GSK3b blocker SB216763 stimulated neurogenesis in NSC
cultures grown in NB27 medium, increasing both the proportion
and number of cells that express PSA-NCAM, as well as the
production of Tuj1, as determined by Tuj1 single and BrdU/Tuj1
double staining (Figure S2). Lithium also reduced the proportion
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e23341Figure 4. Lithium suppresses STAT3 activation. A1. LiCl inhibits serum-induced STAT3 activity in a time-dependent manner. Primary rat NSCs
were cultured in NB27 medium with 0.5% of FBS in the absence (left) or presence of 3 mM lithium (right) for the indicated time. The STAT3 activity
was assessed by detection of phospho-Tyr705-STAT3 (p-STAT3). Similar results were obtained from three independent experiments. B. LiCl inhibits
serum-induced STAT3 activity in a dose-dependent manner. NSCs were cultured with various concentrations of LiCl (0.5, 1, 3, 5 mM) in the presence
of serum for 24 h. C. Morphological changes of NSCs treated with LiCl, AICAR and LiCl+AICAR, respectively. NSCs received no treatment (Control),
lithium (3 mM), AICAR (1 mM), or 45 minutes of lithium pretreatment and addition of AICAR (Li+AICAR). Phase contrast images indicate typical
astroglia morphology. D. AICAR induced STAT3 activation and GFAP expression in a time dependent manner. NSCs were treated with 1 mM AICAR
for the indicated time and P-STAT3, GFAP and GAPDH were assessed by Western Blot analysis. E. STAT3 (E1) activation and GFAP (E2) expression on
NSCs treated with AICAR, lithium or both for 24 hours. F. Expression of Nestin (red) and GFAP (green) on NSCs treated with AICAR, lithium or both for
3 days. G. GFAP expression on NSCs treated with AICAR, lithium or both for 3 days.
doi:10.1371/journal.pone.0023341.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e23341Figure 5. Specific GSK3b blockade has no effect on STAT3 activation and astrogliogenesis. A. Lithium and GSK3b blocker SB216763
inhibit beta catenin phosphorylation (p-beta-Catenin). NSCs were treated with SB216763 (SB2, 10 mM) and LiCl (0, 5, 10, 20 mM) for 30 min. The
GSK3b activity was assessed by detection of p-beta-Catenin. B1. SB216763 had no effect on serum-induced STAT3 activation. NSCs were cultured in
NB27 medium with 0.5% FBS in the presence of 10 mM SB216763 for the indicated time. B2. Serum increased p-STAT3 over time and SB216763 did
not change this curve. Data are expressed as mean 6 sem, averaged from three independent experiments and normalized to control values (n=3, *
P,0.05 vs. control, # P,0.05 vs. SB2 treatment group, one way ANOVA with Dunnett’s post-test). C. STAT3 activation on NSCs treated with lithium
and specific GSK3b inhibitors SB216763 and SB415286. NSCs were treated with LiCl, SB216763, SB415286 and STAT3 inhibitor Stattic at indicated
concentrations for 24 h. D. STAT3 activation on NSCs incubated with 1 mM AICAR for 24 h with or without a 45-minute pretreatment of LiCl (3/
5 mM) or SB216763 (SB2, 10 mM). E. GFAP expression on NSCs stimulated with AICAR for 3 days in the presence or absence of lithium.
doi:10.1371/journal.pone.0023341.g005
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e23341Figure 6. GSK3b inhibition by GID 5-6 does not mimic lithium effect. NSCs were transfected by electrophoresis with liposomes containing
DNA to make Myc-labelled GID5-6, which binds GSK3b and prevents its docking to the cytoplasmic protein axin and phosphorylating beta-catenin.
GID5-6/LP is an ineffective analog of GID5-6. A. Transfection efficiency was assessed by immunostaining the cells for Myc (green) after 24 h. Most of
the cells were nestin+ (red). B. The effect of GID 5-6 transfection on GSK3b activity. GSK3b activity was assessed by immunoblotting for GSK3b
phosphorylated at Ser9 (Ser-P-GSK3b). C. The effect of GID 5-6 transfection on STAT3 activation on NSCs incubated with 0.5% FBS for 24 hours. D.
GID5-6 transfection increased cell numbers by 1.2 fold versus GID5-6 LP transfection group as measured by CyQUANT Assay. E. Neither GID5-6 nor
GID5-6 LP affected the number of GFAP expressing cells. F. GID5-6 transfection had no effect on number of GFAP-expressing cells. Data were
expressed as mean 6 sem obtained from three independent experiments (n=3, * p,0.05 vs. control, t -test). G. GID5-6 transfection did not affect
GFAP level on NSCs but lithium (3 mM) markedly reduced GFAP level.
doi:10.1371/journal.pone.0023341.g006
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the mature glial marker GFAP.
Several investigators have noted these inhibitory effects of
lithium on glial cells [26,53], our further investigation showed that
lithium prevented increases in the number of A2B5+ and GFAP+
cells in NSC cultures but SB216763 did not. In lithium-treated
cultures, counts of A2B5+ and GFAP+ cells did not increase as
much as in untreated cultures. In SB216763-treated cultures, the
number of A2B5+ and GFAP+ cells increased and did not differ
from untreated cultures. This is the first evidence suggesting that
lithium suppressed astrogliogenesis may not through non-GSK
mechanisms.
We hypothesized that lithium blocks phosphorylation of
STAT3, a messenger system known to stimulate astrogliogenesis.
To test this hypothesis, we measured P-Tyr705-STAT3 as an
indicator of STAT3 activation. Adding 0.5% serum or the specific
STAT3 agonist AICAR rapidly increased P-Tyr705-STAT3
protein and GFAP levels in NSC cultures. Lithium blocked this
P-Tyr705-STAT3 and GFAP increase with the same dose-
response as it inhibited astrogliogenesis. Neither SB216763 nor
GID5-6, a highly specific molecular blocker of GSK3b blocked
induced P-Tyr705-STAT3 or GFAP increases. Together these
results provide convincing evidence that lithium inhibits astro-
gliogenesis in NSC cultures by preventing STAT3 phosphoryla-
tion through non-GSK3b mechanisms.
In contrast, GSK3b inhibition stimulates neural progenitor cells
to proliferate. Both lithium and SB216763 markedly increased the
fraction of Ki-67+ cells amongst PSA-NCAM+ cells but not
A2B5+ cells. Ki-67 is a marker of nucleolar and nuclear proteins
expressed by dividing or recently divided cells. In control
untreated cultures, only 14% of PSA-NCAM+ cells labeled for
Ki-67 compared to 51% in 1 mM lithium-treated cultures and
64% in 10 mM SB216763-treated cultures.
Lithium clearly inhibits STAT3 in NSC cultures. Beurel & Jope
[29,54,55] had earlier reported that STAT3 activation depends on
GSK3b in astrocytes and microglia. They found that 20 mM
lithium and other drugs that blocked GSK3b and suppressed
STAT3 activation induced by lipopolysaccharide (LPS) and
interferon-gamma in mouse primary astrocytes and microglia.
Like Beurel & Jope, we found that lithium inhibits STAT3.
However, unlike Beurel and Jope, we found that SB216763 did
not block serum- or AICAR-activation of STAT3. We thus chose
to test another and more specific GSK3b blocker, i.e. GID5-6, to
see if it would inhibit serum- or AICAR activation of STAT3. We
speculate this discrepancy might be due to the different culture
condition and the dominance of regulating pathways among
different cell types.
The cytoplasmic protein axin plays a critical role in GSK
function [36]. In order for GSK3b to phosphorylate (inactivate)
beta-catenin, both molecules must bind to axin. GID5-6 is the part
of axin that specifically binds GSK3b. While overexpression of full
length axin will cause more inactivation of beta-catenin,
expression of GID5-6 should inhibit GSK3b and prevent beta-
catenin phosphorylation. We confirmed that expression of GID 5-
6 blocked GSK3b activity and phosphorylation of beta catenin in
NSCs. However, GID 5-6 did not affect serum- or AICAR-
induced STAT3 activation or astrogliogenesis. These results
indicate that specific blockade of GSK3b does not prevent
STAT3 activation by serum or AICAR.
Thus, our data indicate that GSK3b blockade does not
necessarily inhibit STAT3 activation in NSC cultures. While
GSK3b may play an important role activating STAT3 in
astrocytes and microglia stimulated by LPS and interferon gamma
[29,54,55], GSK3b does not seem to do so in NSC cultures
stimulated by gentler STAT3 agonists. The effect of lithium on
STAT3 and astrogliogenesis appears to be mediated by non-GSK
mechanisms in A2B5+ NSC stimulated by 0.5% serum and
AICAR. Lithium may affect STAT3 directly or indirectly.
In addition to GSK3b, lithium binds to and inhibits several
magnesium-dependent phosphomonoesterases [56,57] and inositol
monophosphatase [58,59]. Lithium also stimulates phosphoinosi-
tol-3-kinase (PI3K) and Akt-1 [60], both of which may negatively
regulate STAT3 by reducing its DNA binding activity [61].
Lithium may regulate STAT3 through any of these pathways.
Alternatively, lithium may bind and inhibit STAT3 directly.
We hope that our study will direct attention towards lithium’s
effects on the JAK (Janus kinase) and STAT3 pathway. This
pathway not only stimulates astrogliogenesis [30,48,51,62,63,64]
but also microglial activation [65,66]. Lithium inhibition of
STAT3 would explain the dramatic reduction of activated
microglia and macrophage due to lithium treatment of NSC
transplanted into spinal cord [21].
STAT3 inhibition may explain lithium’s remarkable lack of
carcinogenicity. Lithium inhibition of GSK3b increases WNT/
beta-catenin, known to be associated with cancer [67,68,69]. Yet,
millions of people have taken lithium for their lifetime without
reports of increased cancer. In fact, lithium reduces formation of
some tumors [29,70,71,72,73]. JAK/STAT3 activation also
increases SOCS (suppressors of cytokine signalling), abnormalities
of which cause cancer [74,75]. By inhibiting STAT3, lithium
should reduce SOCS levels.
Our finding that lithium inhibits astrogliogenesis at 3 mM
should be of interest for those seeking to grow neurons from NSC.
At 1 mM, lithium stimulates neurogenesis without inhibiting
astrogliogenesis. However, at 3 mM, lithium strongly stimulates
neurogenesis and inhibits astrogliogenesis at the same time,
without increasing apoptosis. Growing NSC in 3 mM lithium
should produce predominantly neuronal cultures while growing
them in 1 mM lithium or specific GSK3b blockers will allow
astrocytes to grow. To inhibit astrogliogenesis, higher doses of
lithium should be used.
Lithium is an attractive therapy for CNS regeneration. It is safe
and robustly stimulates proliferation of endogenous [14] and
transplanted neural stem cells [21,40], as well as axonal
regeneration [22,23]. It increases brain concentrations of neuro-
trophins [14,76,77,78,79]. We have now shown that lithium
suppresses astrogliogenesis by inhibiting STAT3, an effect that
other specific GSK3b blockers seem to lack. At 3 mM concen-
trations, lithium thus may prevent or retard gliosis after brain and
spinal cord injury.
In conclusion, lithium stimulates neurogenesis and suppresses
astrogliogenesis by NSCs. We hypothesized that lithium blocks
STAT3, which induces astrogliogenesis and microglial activation.
Lithium, SB216763, and GID5-6 all inhibited GSK3b, prevented
inactivation of beta-catenin, and stimulated neurogenesis. How-
ever, only lithium blocked STAT3 activation and astrogliogenesis
induced by 0.5% serum or the STAT3 agonist AICAR, these
findings indicate that lithium blocked STAT3 activation through
non-GSK3b mechanisms. Lithium inhibition of STAT3 not only
explains why lithium suppresses astrogliogenesis and microglial
activation but also may explain the low carcinogenicity of lithium
in clinical use.
Materials and Methods
For the purposes of this article, we use the term ‘‘neural stem/
progenitor cells’’ to refer to cells isolated from the subventricular
zone of rats. When placed in growth media with epidermal growth
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proliferated and produced neural progenitor cells (NPCs) express-
ing A2B5 and PSA-NCAM, respectively markers for glial-
restricted or neuronal-restricted precursors. When placed in
neurobasal media with B27 (NB27, Invitrogen), the cells
differentiated to express mature neuronal or astroglial markers,
respectively Tuj1 and GFAP. We used the following methods to
prepare and identify NSC, to sort the cells, to assess proliferation
and apoptosis, to quantify GSK3b and STAT3 activation, and to
transfect cells with GID5-6 to block GSK3b.
NSC Preparation and Treatments
We isolated NSCs from neonatal Fischer 344 rats. The Animal
Care and Facilities Committee at Rutgers University approved all
animal procedures (Protocol: Rat Breeding Colony, NO. 99-032).
Newborn rats (P0 or P1) were anesthetized with isoflurane (5%)
and decapitated. Under sterile and ice-cold conditions, we
removed the brain, dissected out the lateral wall of the lateral
ventricle, and dissociated the tissue by gentle trituration with fire-
polished Pasteur pipettes [31].
After filtering the tissue suspension with a cell strainer (BD
Falcon, San Jose, CA, USA), we plated the cells (2610
5 cells per
ml) in NSC culture media (DMEM/F12, Gibco, Grand Island,
NY, USA) containing B27 (1:50, Invitrogen, Carlsbad, CA, USA),
basic fibroblast growth factor (bFGF, 10 ng/ml, R & D, USA),
epidermal growth factor (EGF, 10 ng/ml, R & D, USA), and
Penicillin-Streptomycin (Pen-Strep, 100 IU/ml, Invitrogen). We
will refer to the growth-factor containing media as NSC growth
media.
The cells grew in a 37uC humidified 5% CO2 incubator. We
added growth factors every day, changed media every 2 days, and
passaged the cells after 7 days. We designated first and second
passage cells as P1 and P2, and used only P1 or P2 NSCs in this
study. After passage, the cells were cultured in plates or cover slips
coated with poly-L-lysine (0.01%, Sigma Aldrich, St. Louis, USA)
and laminin (10 mg/ml, Invitrogen), placed in NSC culture media
for 1–2 days, and then transferred to basic neurobasal medium
plus B27 (NB27) for differentiation assays. Lithium chloride
(Sigma Aldrich, St. Louis, USA) was dissolved in Milli-Q water,
AICAR (Sigma Aldrich, St. Louis, USA) and SB216763 (10 mM,
Tocris Bioscience, Ellisville, USA) were dissolved in dimethyl
sulfoxide (DMSO, Sigma Aldrich, St.Louis, USA). We added
lithium chloride and other drugs to the culture medium after the
passage and then assessed the cells by immunocytochemistry or
Western blots 2 to 7 days later, depending on the outcome
measure used.
Immunocytochemistry
For immunocytochemistry, we cultured cells on 12-mm poly-L-
lysine/laminin coated glass cover slips at a density of 2610
4 cells/
cover slip. At specified time points, we immersed the cells for 5–
20 minutes in 4% phosphate-buffered (0.01 M phosphate) para-
formaldehyde, then blocked non-specific binding sites with 10%
normal goat serum (Vector) and solubilized lipids with 0.3%
Triton-X-100 for 1 hour. For surface antigen A2B5 or PSA-
NCAM labeling, the cells were fixed in 4% paraformaldehyde for
only 5 minutes and no Triton-X-100 was added to the blocking or
washing solution. The fixation, blocking, and solubilization were
done at room temperature (RT).
To label cells, we incubated the cells overnight in primary
antibodies diluted in phosphate buffered (0.01 M phosphate)
solution containing 3% normal goat serum and 0.3% Triton-X-
100. Table 1 lists the primary antibodies and their sources. After
washing with phosphate-buffered saline (PBS), we applied
secondary antibodies corresponding to the primary antibody.
The secondary antibodies were conjugated to fluorescent Alexa
568 or 488 (1:400, Molecular Probes) or rhodamine (TRITC) or
FITC-conjugated goat anti-mouse (1:200, Jackson ImmunoRe-
search, goat anti-mouse IgM, m-chain specific). We stained nuclei
with Hoechst 33342 (Molecular Probes, 5 mg/ml) and mounted
the cover slips with Gelmount.
We photographed fluorescent images with a Zeiss Axiovert
200 M epifluorescent microscope or a Zeiss LSM510 confocal
microscope, using 206 magnification and 0.4 aperture, an
AxioCam camera, and Axiovision 4.6 software (Carl Zeiss,
Germany). Cell percentage counts were based on numbers of
nuclei and situation of the nuclei in cells expressing specific
markers. The actual cells number of each lineage was determined
by the combination with the percentage counts and the total
number of cells in each treatment, as determined by proliferation
assay.
Proliferation and Apoptosis Assays
To assess proliferation, we seeded NPC’s on poly-L-lysine/
laminin coated 96-well plates with an initial density of 10
4cells/
well. The cells were cultured in NSC medium for 24 hours and
then in NB27 medium supplemented with lithium and other
drugs. At planned time points, we froze the cells at 270uC
overnight, thawed the cells, and quantified DNA using Cy-
QUANT (Invitrogen) Assay and a Fluoroskan Ascent microplate
reader (Thermo Labsystem, US.) with excitation wavelength at
485610 nm and emission detection wavelength at 530612.5 nm.
We verified that the DNA signal relates linearly to cell number
according to a standard curve provided by the manufacturer. The
data are expressed in mean 6 standard error of mean (mean 6
sem).
To assess apoptosis, we used terminal deoxynucleotidyl
transferase dUTP nick end labeling (DeadEnd
TM Fluorometric
TUNEL System, Promega). After incubating the cells in NB27
medium supplemented with various treatments for different times,
we used 4% paraformaldehyde in PBS to fix the cells for 25 min at
RT, permeabilized the cells with 0.1% Triton X-100 and 0.1%
sodium citrate for 5 min, washed them several times with PBS,
transferred the cells to an equilibration buffer (200 mM potassium
cacodylate, 25 mM Tris-HCl, 0.2 mM DTT, 0.25 mg/ml BSA,
2.5 mM cobalt chloride, pH 6.6) for 10 min, and then immersed
the slides for 60 min at 37uC in a reaction buffer containing
0.3 U/ml terminal deoxynucleotidyl transferase and 50 mM
FITC-fluorescein-12-dUTP. To stop the reaction, we immersed
Table 1. Primary Antibodies used for immunocytochemistry.
Antigen Type Dilution Source
Presumptive
label
Nestin Mouse Monoclonal 1:50 Millipore Stem cell
GFAP Rabbit Polyclonal 1:200 DAKO Astrocyte
Tuj1 Mouse Monoclonal 1:1000 Convance Neuronal
GalC Mouse Monoclonal 1:200 Millipore Oligodendroglia
A2B5 Mouse Monoclonal 1:200 Sigma Glial restricted
PSA-NCAM Mouse Monoclonal 1:300 Millipore Neural restricted
Abbreviation:
GFAP (Glial fibrillary acidic protein).
Tuj1 (Neuronal Class III b-Tubulin);
GalC (Galactosylceramidase);
PSA-NCAM (polysialic acid - neural cell adhesion molecule).
doi:10.1371/journal.pone.0023341.t001
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30 mM sodium citrate, pH 7.0) for 15 min at RT. After staining
the nuclei with 49,6-diamidino-2-phenylindole (DAPI), we mount-
ed the cover slips on slides and visualized the cells with an
epifluorescent microscope equipped with standard fluorescein and
DAPI filters. We counted TUNEL-positive cells in $15 indepen-
dent fields from each of three experiments and expressed the data
as a percent of total DAPI-stained nuclei counted per field.
Western Blots
To quantify phosphorylated and non-phosphorylated GSK3b
and JAK/STAT3 or the other proteins expression, we extracted
proteins from the cells using a radio-immunoprecipitation assay
buffer (RIPA, Sigma-Aldrich, USA), containing 50 mM Tris-HCl
at pH 8.0 with 150 mM NaCl, 1.0% Igepal CA-630 (NP-40),
0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate
(SDS). After pre-clearing the lysates by centrifuging at 12,000 rpm
for 3 minutes, we added phosphatase inhibitor cocktail (1:50,
Sigma) and loaded equal amounts of protein (5–120 mg/sample)
on 10% SDS polyacrylamide gel electrophoresis (SDS-PAGE).
Rainbow molecular weight marker (GE Healthcare) and a Tris-
glycine running buffer (25 mM Tris, 190 mM glycine, 0.1% SDS)
were used.
We transferred the gels to PVDF (polyvinylidene difluoride)
membranes that had been soaked in methanol for 1 min and
equilibrated in transfer buffer containing 25 mM Tris base,
190 mM glycine, 20% methanol, and 0.005% SDS [32]. After
blocking with Tris buffered saline (TBS) buffer containing 0.1%
Tween (TBST) and 5% non-fat dry milk (TBST+5% milk) for
1 hour at RT, we applied primary antibodies in TBST+5% milk
overnight at 4uC, washed with TBST, applied horseradish
peroxidase (HRP) conjugated secondary antibody in PBS+5%
milk for 1 hour, imaged the bound antibodies using ECL plus
Western Blotting Detection System (GE Healthcare, UK),
analyzed with Kodak Molecular Imaging Software (v4.4.4), and
normalized the phosphorylated protein to non-phosphorylated
total protein. Table 2 lists the antibodies used.
Axin GID 5-6 and GID 5-6 LP Plasmid Transfections
Axin is a cytoplasmic protein that binds GSK3b and beta-
catenin, allowing the former to phosphorylate the latter [33].
GSK3b Interaction Domain (aa380 to 404, GID5-6) is a 25 amino
acid polypeptide fragment of axin that binds GSK3b, inhibiting its
activity [34,35,36]. Dr. Peter S. Klein provided myc-tagged GID5-
6 (Axin GID 380–404/pCS2MT) and GID5-6LP (Axin GID
(LeuRPro) 380–404/pCS2MT). GID5-6LP is an ineffective
analog of GID5-6 with proline substituted for leucine.
We used the AmaxaH Rat Neuron 96-well NucleofectorH kit
(Lonza VHPG-1006) to transfect 1 mg of GID5-6 or GID5-6LP
into NSC suspensions. The NucleofectorH (program 96-EM-110)
usually transfects 50–65% of 2.5–3.0610
5 cells per well. To
identify cells that had been successfully transfected, we immuno-
stained the cells for myc (1:200, Cat 2278, Cell Signaling
Technology) after 24 hours in NSC growth media.
For immunocytochemistry, we grew 3610
4cells on cover slips.
To assess proliferation, we seeded 10
4 cells per well and counted
before and after 7 days in culture. For protein analyses, we grew
the cells in 6-well plates at 5610
5cells/well. After transferring to
NB27 media, we assessed the cells at 24 hours for GSK3b and
STAT3 phosphorylation.
Statistical Analyses
Data in the figures represent mean6sem and n indicates the
number of experiments. We used the Student’s unpaired t-test to
compare two groups and analysis of variance (ANOVA) to
compare multiple groups, followed by Dunnett’s posthoc test to
compare pairs of groups. A p-value of ,0.05 indicates
significance.
Supporting Information
Figure S1 Lithium but not SB216763 suppresses S100b
expression. NSCs were grown for 7 days in NB27 containing
LiCl (0.5, 1.0, 3.0 mM) or SB216763 (10 mM) and then stained for
S100b (red); nuclei were stained with Hoechst 33342 (blue). The
photomicrographs (A1) show representative fields from each
treatment group (Control, 3 mM LiCl and SB21763). The graphs
show actual number counts of S100b+ cells (A2), normalized to
untreated control counts. Lithium reduced the S100b+ cells
number by 0.7260.08 fold in 0.5 mM LiCl (P,0.05) compared to
control, 0.5160.09 in 1.0 mM LiCl (P,0.05), 0.4460.11 in
3.0 mM LiCl (P,0.05). In contrast, SB216763 treatment did not
reduce astrocyte number (1.160.09 fold versus Control, P.0.05).
Data are expressed as mean 6 sem from three independent
experiments (n=3, * denotes P,0.05 vs. control, one way
ANOVA with Dunnett’s post-test).
(TIF)
Figure S2 Both lithium and SB216763 stimulate neuro-
genesis by NSCs. NSCs were differentiated in NB27 medium
containing LiCl (1.0 mM) or SB216763 (10 mM) for 7–8 days.
BrdU (10 mM, Sigma) was added to cultures 2 days before fixation.
Table 2. Primary Antibodies used for Western blot.
Antigen Type Comments
Phospho-Tyr705-STAT3 Rabbit Monoclonal Phosphorylated STAT3 at the Tyr705 site.
STAT3 Rabbit Monoclonal Non-phosphorylated STAT3
Phospho-Beta-catenin Rabbit Monoclonal Phosphorylated beta-catenin at Ser33/37/Thr41
Beta-catenin Rabbit Monoclonal Non-phosphorylated beta-catenin
Ser9-Phospho-GSK3b Rabbit Monoclonal Phosphorylated GSK3b at the Ser9 site
GFAP Mouse Monoclonal Maker as mature astrocytes
GAPDH Rabbit Monoclonal Housekeeping Gene
Abbreviations:
STAT3 (Signal transducer and activator of transcription 3),
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0023341.t002
Lithium Suppresses Astrogliogenesis via STAT3
PLoS ONE | www.plosone.org 12 September 2011 | Volume 6 | Issue 9 | e23341Cells were stained for Tuj1 (Green) and BrdU (red, A1). The
graphs show the percentage of BrdU+ cells in Tuj1+ cells (A2),
both LiCl and SB216763 significantly increased the BrdU fraction
in Tuj1+ cells. Control group: 4.861.2%; lithium (1 mM) group:
14.362.8% (P,0.05); SB216763 (10 uM): 25.762.6%, (P,0.05).
Data are expressed as mean 6 sem from three independent
experiments (n=3, * denotes P,0.05 vs. control, one way
ANOVA with Dunnett’s post-test).
(TIF)
Figure S3 The co-localization of PSA/NCAM and Tuj1
after 5 days of differentiation. NSCs were grown for 5 days
in NB27 containing LiCl (0.5, 1.0, 3.0, 5 mM) or SB216763
(10 mM) and then stained for Tuj1 (red) and PSA/NCAM (green),
nuclei were stained with Hoechst 33342 (blue). Most Tuj1+ cells
co-localized with PSA/NCAM after 5 days. The photomicro-
graphs (A1) show representative fields of the co-localization of
PSA/NCAM and Tuj1 from each treatment group (control,
1 mM LiCl, SB216763). The graphs show the percentage of Tuj1
and PSA/NCAM double positive cells out of total cells (A2). Data
are expressed as mean 6 sem from three independent experiments
(n=3, * denotes P,0.05 vs. control, one way ANOVA with
Dunnett’s post-test).
(TIF)
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